Objectives. This study compared the long-term effects of complete atrioventricular junction (AVJ) ablation with those of AVJ modification in patients with medically refractory atrial fibrillation (AF).
Previous reports (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) have demonstrated that complete catheter ablation of the atrioventricular junction (AVJ) with permanent pacing improved the quality of life (QOL), the ability to perform activities of daily life (ADL) and ventricular performance in patients with medically refractory atrial fibrillation (AF). Recently, some studies (11) (12) (13) (14) (15) have demonstrated that radiofrequency catheter modification of atrioventricular (AV) conduction could achieve control of ventricular rate (VR) during AF without the need for pacemaker implantation. However, questions arose regarding the long-term effects of radiofrequency catheter modification of the AVJ on QOL, symptoms of AF, ADL and left ventricular (LV) function in these patients. Furthermore, no previous studies have compared the long-term effects of complete AVJ ablation with those of AVJ modification in patients with medically refractory AF. The purpose of the present study was to prospectively compare the long-term effects on QOL and cardiac performance after complete AVJ ablation and permanent pacing with those after AVJ modification in patients with medically refractory AF with or without depressed LV function.
Methods
Patients. This study included 60 patients with medically refractory paroxysmal atrial fibrillation (PAF) or chronic atrial fibrillation (CAF). All patients had frequent attacks of symptomatic AF with rapid ventricular response documented by electrocardiographic recordings. Patients with a standard indi-cation for permanent pacemaker implantation-for example, AF with long pause or with symptomatic bradycardia-were excluded from the study.
Electrophysiologic study and radiofrequency catheter ablation. Informed consent was obtained from all patients, and the study protocol was approved by the Human Research Committee at our institution. All patients were randomly assigned to receive complete AVJ ablation with permanent pacing or AVJ modification according to a random number table. As described previously, a 7F quadripolar electrode catheter with a 4-mm distal electrode (2-to 5-mm spacing between electrodes and a deflectable tip, Mansfield, Boston Scientific) was used to deliver radiofrequency energy (Radionic-3C, Radionics); a large electrosurgical paddle (Valleylab) positioned on the posterior chest wall served as the indifferent electrode (15, 16) .
In patients who received AVJ ablation and permanent pacing, the ablation catheter was placed across the tricuspid valve and positioned to record the largest His bundle electrogram associated with the largest atrial electrogram. Energy was delivered until complete AV block was achieved and then continued for an additional 30 s. If no change in AV conduction was observed after 60 s of radiofrequency application, the catheter was repositioned and a repeat attempt was made. This procedure was repeated until complete AV block persisted for 30 min. A 5F bipolar catheter was then introduced through the right jugular vein into the right ventricular apex for temporary pacing. Two days after ablation, a programmable permanent pacemaker (ventricular rate-adaptive mode) was implanted in these patients. During the study period, the pacemaker was programmed at a basic rate of 70 beats/min and at an activity upper sensor rate of 120 beats/min. Pacemaker implantation time was included in determining the procedure duration and fluoroscopy time.
In patients who received AVJ modification, as described previously (15) , the VR of AF was measured for 1 min in the baseline state and after a steady state effect had been reached during the infusion of different doses of isoproterenol (2 and 4 g/min for 10 min). The ablation catheter was initially positioned against the posterior septum at the level of, or lower than, the coronary sinus ostium to record a stable electrogram for Ն10 s with a maximal atrial to ventricular electrographic ratio Յ0.5. Radiofrequency energy was delivered for 20 s at a power of 30 W. If there was no change in VR or no appearance of accelerating junctional rhythm within 20 s, a higher energy level (step-up 5 W for 20 s, up to 40 W) was delivered to the original site. Whenever there was an abrupt lengthening of the RR interval or appearance of the accelerating junctional rhythm, the application of energy was immediately discontinued. If the VR was still higher than the end point VR, a higher energy level was delivered to the effective site or the ablation site was changed. Radiofrequency energy was delivered to three close sites of posterior and inferior regions before the ablation catheter was repositioned progressively upward (more superior and anterior positions) along the tricuspid annulus. Radiofrequency energy was never delivered at the upper third of the atrial septum, where a His bundle potential was visible. The end point of the procedure was an average VR of ϳ120 to 130 beats/min or an average VR of ϳ70% to 75% of the baseline VR during infusion of isoproterenol (4 g/min) (15) .
QOL. All patients were followed up for Ն6 months. All kept a detailed QOL diary that included general QOL, frequency of significant symptoms, symptoms during attacks and ADL. All patients visited a special clinic at 1 and 2 weeks and then every month to assess medication, number of hospital admissions, emergency room visits and the QOL diary. Drugs considered in this assessment were digoxin and any agent in Vaughan Williams class I to IV.
Subjective perception of QOL was assessed by a semiquantative questionnaire before and at 1 and 6 months after ablation. Patients were asked to compare their general QOL, frequency of significant symptoms, symptoms during attacks and ADL with those before ablation. The assessment of general QOL before and after radiofrequency catheter ablation was scored as 0 ϭ very good, 1 ϭ good, 2 ϭ moderate, 3 ϭ poor, and 4 ϭ very bad. The frequency of AF was scored as 0 ϭ none, 1 ϭ very infrequent, 2 ϭ sometimes, and 3 ϭ very frequent. As described previously, each patient was also asked to quantify each of the following symptoms resulting from AF on a score scale of 0 ϭ no symptoms, 1 ϭ mild, 2 ϭ moderate, 3 ϭ severe. The symptoms included palpitation, asthenia (sensation of fatigue), effort dyspnea, rest dyspnea, dizziness, chest oppression, blurred vision and syncope (0 ϭ none, 1 ϭ presyncope, 2 ϭ syncope) (16, 17) . Patients scored the impairment of their ability to perform ADL before and at 1 and 6 months after ablation.
Activity limitation scores were 0 ϭ not limited, 1 ϭ mildly limited, 2 ϭ moderately limited, and 3 ϭ severely limited. The activities of daily life assessed were 1) bathing, 2) walking on level surface, 3) climbing stairs, 4) carrying groceries, and 5) vigorous exercise.
Cardiac performance. Cardiac performance was evaluated by echocardiography and radionuclide angiography in all patients within 24 h after ablation (baseline evaluation) and at 1 and 6 months after ablation. Antiarrhythmic agents with a negative inotropic effect were discontinued for Ն5 half-lives, and amiodarone was stopped Ն30 days before each study of cardiac performance (6) . In patients who received AVJ abla- (19) . A symptom-limited treadmill exercise test using the modified Bruce protocol was performed before and at 1 and 6 months after ablation, if the patients could tolerate the test. Statistical analysis. All continuous variables are expressed as mean value Ϯ SD. The chi-square test with the Yates correction or Fisher exact test was used to assess the nonparametric data, and a Student t test was used to compare continuous variables between two groups. A two-way repeated measures analysis of variance with the Student-Newman-Keuls test was used to compare QOL and cardiac performance before and at 1 and 6 months after ablation. Regression analysis was used to assess the correlation between two variables. To assess the independent variables in predicting the change of QOL and cardiac performance after ablation, multivariate logistic regression analysis was carried out by considering all variables identified as p Ϲ 0.25 in the univariate analysis. The variables included for analysis were baseline patient characteristics (age, gender, type of AF, duration of AF, left atrial dimension, LVEF, VR in Holter recording, and presence of other heart disease) and the baseline score for general QOL, frequency of significant symptoms, symptoms during attacks, ADL, number of hospital and emergency room admissions and number of previous antiarrhythmic drugs. A p value Ͻ 0.05 was considered statistically significant.
Results
Baseline data ( Table 1 ). The mean age was 69 Ϯ 9 years in patients after AVJ ablation with permanent pacing and 66 Ϯ 10 years in patients after AVJ modification. The proportion of patients with PAF, the mean duration of symptoms suggestive of AF and rest and maximal VR during AF were similar in the two groups. A mean of 4.9 Ϯ 1.9 antiarrhythmic drugs for preventing AF or decreasing VR during AF had been tried unsuccessfully in the group after AVJ ablation and a mean of 5.3 Ϯ 2.3 antiarrhythmic drugs had been tried unsuccessfully in the group after AVJ modification. New York Heart Association functional class, left atrial dimension measured by echocardiography and incidence of cardiovascular diseases were similar in the two treatment groups.
Ablation results. In all patients who received AVJ ablation and permanent pacing, complete ablation of the AV conduction system was successful and without complications. One patient had recurrence of AV conduction within 24 h after ablation; he had successful ablation in the second session without recurrence of a conduction. All patients after complete AVJ ablation with permanent pacing were discharged from the hospital with completely paced rhythm, and none manifested AV conduction during a mean follow-up period of 16 Ϯ 6 months (range 10 to 22). The rest and maximal paced VR 6 months after ablation were 74 Ϯ 3 and 114 Ϯ 5 beats/min, respectively. In 4 of the 15 patients with PAF, pacemaker syndromes were documented; these included mild dizziness in 3 patients and mild weakness in 1 patient. Twenty-eight of the 30 patients who received AVJ modification had successful modification; the other 2 had complete AV block immediately after the modification procedure. A permanent pacemaker (ventricular rate-adaptive mode) was implanted in the two patients with AV block. These two patients were included in the analysis based on intention to treat. Late AV block or symptomatic bradycardia was not observed in any of the patients with successful modification during the follow-up period (mean 15 Ϯ 5 months, range 9 to 21). The minimal, rest and maximal values for VRs during AF 6 months after modification were 64 Ϯ 7, 87 Ϯ 14 and 132 Ϯ 21 beats/min, respectively. The maximal cycle length during AF was 1,052 Ϯ 123 ms. The major differences between patient groups were the significantly higher radiofrequency pulses and longer fluoroscopy time in patients who received AVJ modification. In both groups, patients with CAF received warfarin sodium (Coumadin) and those with PAF received aspirin during follow-up. Early or late complications (including sudden death and stroke or thromboembolism related to AF) did not occur in either group.
Comparisons of AVJ ablation and AVJ modification. QOL (Table 2 ). In the two groups, general QOL improved significantly and the frequency of major symptoms decreased significantly at 1 and 6 months of follow-up. After complete AVJ ablation, all the symptoms during attacks decreased significantly at 1 and 6 months of follow-up. After AVJ modification, symptom scores including those for palpitation, asthenia, effort dyspnea and rest dyspnea during attacks improved significantly at 1 and 6 months of follow-up; however, symptom scores for dizziness, chest oppression, blurred vision and syncope remained unchanged. The ability to bathe, walk on level surfaces and climb stairs improved significantly in the two groups at 1 and 6 months of follow-up. Although the ability to carry groceries and perform vigorous exercise remained unchanged, the pooled score of ADL changed significantly at 1 and 6 months of follow-up in the two groups. The consumption of health care resources, including frequency of hospital admission and emergency room visits for AF and entrance into antiarrhythmic drug trials, decreased significantly 6 months after AVJ ablation or modification. During the study period, cardiac drugs with negative chronotropic effects were continued because of other cardiovascular diseases in 11 (37%) of the 30 patients after complete AVJ ablation; these drugs included atenolol in 5, verapamil in 3 and digoxin in 3. Twelve (40%) of the 30 patients after AVJ modification received drugs with negative chronotropic effects; these drugs included atenolol in 5, verapamil in 2 and digoxin in 5.
Comparisons between the two treatment groups showed that each variable of QOL obtained before AVJ ablation or modification was similar. The 1-and 6-month follow-up studies showed that patients who received complete AVJ ablation had significantly greater improvement in scores for general QOL, frequency of significant symptoms and symptoms during attacks, including palpitation, dizziness, chest oppression, blurred vision and syncope, than did those who received AVJ modification. However, the symptom scores for asthenia, effort dyspnea and rest dyspnea during attacks were similar in both groups at 1 and 6 months of follow-up, as were the symptom scores for ADL. No variable in consumption of health care resources was significantly different between the two groups at 6 months of follow-up. Cardiac performance. Twenty-five of the 30 patients who received complete AVJ ablation and 24 of the 30 patients who received AVJ modification had a satisfactory two-dimensional echocardiogram available for analysis. In both groups, LV end-diastolic dimension was unchanged, LV end-systolic dimension was significantly decreased and LVEF was significantly increased at 1 and 6 months of follow-up. Furthermore, LVEF measured by radionuclide angiography was significantly increased at 1 and 6 months after complete AVJ ablation or AVJ modification (Table 3 ). There was a strong relation between the LVEF measured by radionuclide angiography and the results obtained by two-dimensional echocardiography (r ϭ 0.91, p Ͻ 0.05). Baseline and 1-and 6-month follow-up studies showed that LV end-diastolic dimension, LV endsystolic dimension and LVEF measured by echocardiography and by radionuclide angiography were similar in the two groups (Table 3) .
Twenty-eight of the 60 patients could not complete the exercise test before ablation because of claudication (5 patients), asthenia (10 patients), dyspnea (6 patients) and chest pressure (7 patients). Fifteen of the 30 patients who received AVJ ablation and permanent pacing completed the treadmill exercise tests; their mean exercise time was 4.2 Ϯ 0.6 min before ablation and 6.1 Ϯ 0.5 min 1 month (p Ͻ 0.01) and 5.8 Ϯ 0.4 min 6 months after ablation (p Ͻ 0.01). The mean maximal VR was 156 Ϯ 15 beats/min before and 114 Ϯ 5 beats/min 1 month (p Ͻ 0.01) and 113 Ϯ 6 beats/min 6 months after ablation (p Ͻ 0.01). Seventeen of the 30 patients who received AVJ modification completed the treadmill exercise tests; their mean exercise time was 4.4 Ϯ 0.5 min before ablation and 6.2 Ϯ 0.6 min 1 month (p Ͻ 0.01) and 6.0 Ϯ 0.7 min 6 months after ablation (p Ͻ 0.01). The mean maximal VR was 158 Ϯ 17 beats/min before and 137 Ϯ 14 beats/min 1 month (p Ͻ 0.01) and 135 Ϯ 17 beats/min 6 months after ablation (p Ͻ 0.01). The mean exercise time was similar between the two groups before and 1 and 6 months after ablation.
Subgroup analysis based on LV function. Sixteen of the 30 patients who received complete AVJ ablation and 17 of the 30 patients who received AVJ modification had a baseline LV ejection fraction м50% measured by radionuclide angiography. The general QOL and scores for frequency of significant symptoms and symptoms during attacks of AF improved significantly after complete AVJ ablation or AVJ modification, independent of LV function. The consumption of health care resources decreased significantly after complete AVJ ablation or AVJ modification, independent of LV function. The ability to perform ADL was not changed in patients with a baseline LVEF м50%, but the capacity to bathe, walking on level surfaces and climb stairs improved significantly after AVJ ablation or modification in patients with a baseline LVEF Ͻ50%. No variable of cardiac performance was changed in patients with a baseline LVEF м50%, but LV end-systolic dimension measured by echocardiography decreased significantly and LVEF measured by echocardiography and radionuclide angiography increased significantly after AVJ ablation or modification in patients with a baseline LVEF Ͻ50%. In patients with a baseline LVEF Ͻ50%, the percent change in pooled score of ADL correlated with the percent change in LVEF obtained at 6 months after complete AVJ ablation (r ϭ Ϫ0.84, p Ͻ 0.01, slope ϭ 0.71) and AVJ modification (r ϭ Ϫ0.83, p Ͻ 0.01, slope ϭ 0.76), and the slope of the regression line was similar between the two subgroups (p ϭ 0.31).
Factors influencing improvement in QOL and cardiac performance. Patients with PAF had an improvement in QOL and cardiac performance after AVJ ablation with permanent pacing similar to that of patients with CAF (Table 4 ). The improved effects of AVJ modification on QOL and cardiac performance in patients with PAF were also similar to those of patients with CAF (Table 5) . Furthermore, none of the analyzed factors could independently predict improvement in QOL and cardiac performance after AVJ ablation or AVJ modification.
Discussion
Major findings. Compared with AVJ modification, AVJ ablation with permanent pacing had a significantly greater ability to decrease the frequency of attacks and extent of symptoms of AF, and the patients who received this procedure were more satisfied with their general well-being. However, both AVJ ablation with permanent pacing and AVJ modification were effective in improving general QOL, decreasing the frequency of significant symptoms, alleviating symptoms during attacks and decreasing the consumption of health care resources in patients with medically refractory AF. Furthermore, in patients with depressed LV function, both methods were similarly efficacious in improving LVEF and ADL scores. These improvements in QOL and cardiac performance occurred within 1 month after ablation and they were maintained through 6 months after the procedure.
Comparisons between AVJ ablation and AVJ modification. Quality of life. Kay et al. (2) first reported that QOL could be improved in 12 consecutive patients with PAF after catheter ablation using direct current. Brignole et al. (8) showed that radiofrequency ablation of AVJ with permanent pacing significantly improved QOL and ADL score in 23 patients with CAF and flutter. Fitzpatrick et al. (9) recently reported positive outcomes in terms of QOL, ADL and consumption of health care resources after radiofrequency ablation of AVJ with permanent pacing in 107 patients who had established CAF or PAF. In the present study, AVJ ablation with permanent pacing had similar effects as in the previous studies.
The present study demonstrated that AVJ modification significantly improved general QOL and decreased the frequency of significant symptoms and consumption of health care resources. The decrease in VR during AF after modification resulted in the lessening of symptoms, such as palpita- Tables 2 and 3. tion, asthenia, effort dyspnea and rest dyspnea. However, symptoms including dizziness, chest oppression, blurred vision and syncope did not significantly lessen after AVJ modification. Morady et al. (20) also demonstrated that ϳ70% of patients had lessening of symptoms after AVJ modification; however, their study patients were not randomized to receive AVJ ablation or modification therapy (20) . Furthermore, the present study used a score scale to assess the symptoms resulting from AF. We demonstrated that patients after AVJ ablation with permanent pacing, as compared with AVJ modification, had a significantly greater lessening of the frequency and symptoms of AF including palpitation, dizziness, chest oppression, blurred vision and syncope. The patients who received AVJ ablation with permanent pacing became asymptomatic, perhaps because of better control of VR and regularization of ventricular rhythm during AF; the patients who received AVJ modification remained symptomatic, perhaps because of the irregular ventricular rhythm of AF. Furthermore, the patients with PAF remained symptomatic, perhaps because of their awareness of the onset and offset of an episode after AVJ modification. The present study also demonstrated that in patients with depressed LV function, both treatments had a similar efficacy in improving the capacity to perform ADL including bathing, walking on level surfaces and carrying groceries. By quantifying and correlating the changes in LV performance and ADL, this study also offered a direct explanation for the increase in performance of ADL after AVJ ablation with permanent pacing or AVJ modification.
Cardiac performance. In this study, echocardiographic measurements at three evaluations were obtained during ventricular pacing at the same VR in patients after AVJ ablation and permanent pacing. Therefore, abnormal septal motion during right ventricular pacing should be of minor significance to our results (21) . Patients after AVJ modification had the same atrial rhythm and a similar VR (difference Ͻ10 beats/min) at three evaluations; this study design excluded VR as an artifact of initially depressed LVEF. Furthermore, the evaluation of baseline myocardial function within 24 h after ablation seemed applicable, because substantial changes in myocardial mechanics might not be expected until day 10 after abolition of the tachycardia (22, 23) . Although the effects of oral amiodarone might exist after discontinuation for 30 days (seven patients), this drug appeared to have little if any negative inotropic action (24) .
Patients with baseline depressed LV function had a significant improvement in LVEF after AVJ modification. This observation supported the view that baseline LV dysfunction might result from rapid VR and that control of the rapid VR would lead to subsequent improvement in ventricular function. Several mechanisms of tachycardia-induced LV dysfunction have been proposed (25) (26) (27) (28) , including myocardial ischemia with depressed contractility, depletion of high energy phosphate stores, activation of the sympathetic nervous system and renin-angiotensin system and depletion of atrial natriuretic factor.
Compared with AVJ modification, AVJ ablation with permanent pacing had the advantages of better control of rapid VR and regularization of ventricular rhythm; however, it had the disadvantages of asynergic ventricular contraction and the loss of AV synchrony during sinus rhythm in patients with PAF. Several recent studies (29, 30) have emphasized that right ventricular apical pacing might worsen LV function in patients with baseline depressed LV function. Some studies (31, 32) have demonstrated that irregularity of ventricular rhythm, independent of VR, might also contribute to impairment of cardiac function during AF. Our results suggest that the effects of complete AVJ ablation with permanent pacing on cardiac performance were similar to those of AVJ modification in patients with depressed LV function.
Study limitations. Several limitations to this study must be recognized. 1) A ventricular rate-adaptive mode pacemaker was implanted in all patients after complete AVJ ablation. Dual-chamber rate-responsive pacemakers will maintain normal AV synchrony during periods of sinus rhythm in some patients with PAF.
2) The QOL instruments used have not been rigorously validated for this patient group. 3) Whether the present results will be maintained over a longer follow-up period is unknown. 4) Although the initial study design included a treadmill exercise test before and after ablation, only half of the patients in this study were tolerant of the exercise test before ablation. 5) Anxiety regarding the sudden and unpredictable onset of severe symptoms characteristic of PAF is likely to have been the major reason for self-imposed limitations in performing ADL, affecting the QOL of the study patients. Similar changes in QOL and performance of ADL may not occur in less symptomatic patient groups. 6) We did not have a control group of patients with similar AF treated without catheter ablation. However, it would be difficult to withhold catheter ablation from patients with medically refractory AF and rapid VR. 7) Participants who undergo an invasive procedure may report improvements in QOL simply as a result of being part of a treatment group. 8) A coexisting chronic condition such as arthritis and congestive heart failure may limit the ability to perform ADL in these old patients (10, 33) .
Conclusions. The present study suggests that both AVJ ablation with permanent pacing and AVJ modification are safe and effective means of improving general QOL and cardiac performance in patients with medically refractory AF. These improvements occurred within 1 month after ablation and were maintained through 6 months after the procedure. Furthermore, AVJ ablation with permanent pacing had a significantly greater effect than that of AVJ modification in decreasing the frequency of attacks and extent of symptoms of AF, and the patients who received this procedure were more satisfied with their general well-being.
